+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Schizophrenia Drugs Market Analysis 2019

  • ID: 4857830
  • Report
  • November 2019
  • Region: Global
  • 121 pages
  • Syngene Research
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Alexza Pharmaceuticals
  • Allergan
  • Braeburn Pharmaceuticals
  • Eli Lilly
  • Merck & Co
  • Otsuka Pharma
  • MORE
The Schizophrenia Drugs market is expected to reach $10.16 billion by 2026 growing at a CAGR of 4.5% during 2018 to 2026. Schizophrenia is a serious disorder that affects how a person thinks, feels, and acts. People suffering from this disease have difficulty distinguishing between real and reel, and expressing emotions. Males are often affected with this disease. Antipsychotic drugs are generally prescribed, as they help to control symptoms like disorganized thinking, hallucinations, and delusions by blocking specific chemicals in the brain like serotonin and dopamine.

Factors such as increased demand for enhanced therapy among patients, improvement in healthcare infrastructure, and rise in R&D expenditure in the field of medicine are driving the market growth. Though, social stigma of mental health conditions restrains the market growth. Moreover, rising healthcare expenditure is the opportunity for the schizophrenia drugs market.

Based on therapeutic class, the second-generation segment is going to have a lucrative growth during the forecast period, as it is the most commonly preferred medication. Also, it is FDA approved for acute treatment of manic or mixed episodes of bipolar disorder, maintenance treatment of the bipolar disorder and irritability associated with autistic disorders.

The key vendors mentioned are Eli Lilly, Johnson & Johnson, Pfizer, Bristol-Myers Squibb, Vanda Pharma, Otsuka Pharma, Alkermes, Sumitomo Dainippon, Allergan, AstraZeneca , Titan Pharmaceutical, Alexza Pharmaceuticals, Novartis, Yoshitomi Yakuhin Corporation, Braeburn Pharmaceuticals, and Merck & Co .

Types Covered:
  • Catatonic Schizophrenia
  • Disorganized Schizophrenia
  • Paranoid Schizophrenia
  • Schizoaffective Disorder
Therapeutic Classes Covered:
  • First-Generation
  • Second-Generation
  • Third-Generation
Treatment Types Covered:
  • Antipsychotics
  • Coordinated Specialty Care (CSC)
  • Psychosocial Treatments
  • Thioxanthenes
  • Oral
  • Injectables
Applications Covered:
  • Unipolar Depression
  • Bipolar Disorder
  • Schizophrenia
  • Dementia
End Users Covered:
  • Hospital Pharmacies
  • Clinics
  • Rehabilitation Centers
  • E-Commerce
  • Drug Stores/Retail Pharmacies
Regions Covered:
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa
Key Questions Answered in this Report:
  • How this market evolved since the year 2016
  • Market size estimations, forecasts and CAGR for all the segments presented in the scope
  • Key Market Developments and financials of the key players
  • Opportunity Analysis for the new entrants
  • SWOT Analysis of the key players
  • Fastest growing markets analysed during the forecast period

*Please Note: This report will be delivered within 48 hours of ordering.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Alexza Pharmaceuticals
  • Allergan
  • Braeburn Pharmaceuticals
  • Eli Lilly
  • Merck & Co
  • Otsuka Pharma
  • MORE
1 Market Synopsis

2 Research Outline
2.1 Research Snapshot
2.2 Research Methodology
2.3 Research Sources
2.3.1 Primary Research Sources
2.3.2 Secondary Research Sources

3 Market Dynamics
3.1 Drivers
3.2 Restraints

4 Market Environment
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Schizophrenia Drugs Market, By Type
5.1 Introduction
5.2 Catatonic Schizophrenia
5.3 Disorganized Schizophrenia
5.4 Paranoid Schizophrenia
5.5 Schizoaffective Disorder

6 Global Schizophrenia Drugs Market, By Therapeutic Class
6.1 Introduction
6.2 First-Generation
6.3 Second-Generation
6.4 Third-Generation

7 Global Schizophrenia Drugs Market, By Treatment Type
7.1 Introduction
7.2 Antipsychotics
7.3 Coordinated Specialty Care (CSC)
7.4 Psychosocial Treatments
7.5 Thioxanthenes
7.6 Oral
7.7 Injectables

8 Global Schizophrenia Drugs Market, By Application
8.1 Introduction
8.2 Unipolar Depression
8.3 Bipolar Disorder
8.4 Schizophrenia
8.5 Dementia

9 Global Schizophrenia Drugs Market, By End User
9.1 Introduction
9.2 Hospital Pharmacies
9.3 Clinics
9.4 Rehabilitation Centers
9.5 E-Commerce
9.6 Drug Stores/Retail Pharmacies

10 Global Schizophrenia Drugs Market, By Geography
10.1 North America
10.2 Europe
10.3 Asia Pacific
10.4 South America
10.5 Middle East & Africa

11 Strategic Benchmarking

12 Vendors Landscape
12.1 Eli Lilly
12.2 Johnson & Johnson
12.3 Pfizer
12.4 Bristol-Myers Squibb
12.5 Vanda Pharma
12.6 Otsuka Pharma
12.7 Alkermes
12.8 Sumitomo Dainippon
12.9 Allergan
12.10 AstraZeneca
12.11 Titan Pharmaceutical
12.12 Alexza Pharmaceuticals
12.13 Novartis
12.14 Yoshitomi Yakuhin Corporation
12.15 Braeburn Pharmaceuticals
12.16 Merck & Co

List of Data Tables
Table 1 Global Schizophrenia Drugs Market Outlook, By Region (2016-2026) ($MN)
Table 2 Global Schizophrenia Drugs Market Outlook, By Type (2016-2026) ($MN)
Table 3 Global Schizophrenia Drugs Market Outlook, By Catatonic Schizophrenia (2016-2026) ($MN)
Table 4 Global Schizophrenia Drugs Market Outlook, By Disorganized Schizophrenia (2016-2026) ($MN)
Table 5 Global Schizophrenia Drugs Market Outlook, By Paranoid Schizophrenia (2016-2026) ($MN)
Table 6 Global Schizophrenia Drugs Market Outlook, By Schizoaffective Disorder (2016-2026) ($MN)
Table 7 Global Schizophrenia Drugs Market Outlook, By Therapeutic Class (2016-2026) ($MN)
Table 8 Global Schizophrenia Drugs Market Outlook, By First-Generation (2016-2026) ($MN)
Table 9 Global Schizophrenia Drugs Market Outlook, By Second-Generation (2016-2026) ($MN)
Table 10 Global Schizophrenia Drugs Market Outlook, By Third-Generation (2016-2026) ($MN)
Table 11 Global Schizophrenia Drugs Market Outlook, By Treatment Type (2016-2026) ($MN)
Table 12 Global Schizophrenia Drugs Market Outlook, By Antipsychotics (2016-2026) ($MN)
Table 13 Global Schizophrenia Drugs Market Outlook, By Coordinated Specialty Care (CSC) (2016-2026) ($MN)
Table 14 Global Schizophrenia Drugs Market Outlook, By Psychosocial Treatments (2016-2026) ($MN)
Table 15 Global Schizophrenia Drugs Market Outlook, By Thioxanthenes (2016-2026) ($MN)
Table 16 Global Schizophrenia Drugs Market Outlook, By Oral (2016-2026) ($MN)
Table 17 Global Schizophrenia Drugs Market Outlook, By Injectables (2016-2026) ($MN)
Table 18 Global Schizophrenia Drugs Market Outlook, By Application (2016-2026) ($MN)
Table 19 Global Schizophrenia Drugs Market Outlook, By Unipolar Depression (2016-2026) ($MN)
Table 20 Global Schizophrenia Drugs Market Outlook, By Bipolar Disorder (2016-2026) ($MN)
Table 21 Global Schizophrenia Drugs Market Outlook, By Schizophrenia (2016-2026) ($MN)
Table 22 Global Schizophrenia Drugs Market Outlook, By Dementia (2016-2026) ($MN)
Table 23 Global Schizophrenia Drugs Market Outlook, By End User (2016-2026) ($MN)
Table 24 Global Schizophrenia Drugs Market Outlook, By Hospital Pharmacies (2016-2026) ($MN)
Table 25 Global Schizophrenia Drugs Market Outlook, By Clinics (2016-2026) ($MN)
Table 26 Global Schizophrenia Drugs Market Outlook, By Rehabilitation Centers (2016-2026) ($MN)
Table 27 Global Schizophrenia Drugs Market Outlook, By E-Commerce (2016-2026) ($MN)
Table 28 Global Schizophrenia Drugs Market Outlook, By Drug Stores/Retail Pharmacies (2016-2026) ($MN)
Table 29 North America Schizophrenia Drugs Market Outlook, By Country (2016-2026) ($MN)
Table 30 North America Schizophrenia Drugs Market Outlook, By Type (2016-2026) ($MN)
Table 31 North America Schizophrenia Drugs Market Outlook, By Therapeutic Class (2016-2026) ($MN)
Table 32 North America Schizophrenia Drugs Market Outlook, By Treatment Type (2016-2026) ($MN)
Table 33 North America Schizophrenia Drugs Market Outlook, By Application (2016-2026) ($MN)
Table 34 North America Schizophrenia Drugs Market Outlook, By End User (2016-2026) ($MN)
Table 35 Europe Schizophrenia Drugs Market Outlook, By Country (2016-2026) ($MN)
Table 36 Europe Schizophrenia Drugs Market Outlook, By Type (2016-2026) ($MN)
Table 37 Europe Schizophrenia Drugs Market Outlook, By Therapeutic Class (2016-2026) ($MN)
Table 38 Europe Schizophrenia Drugs Market Outlook, By Treatment Type (2016-2026) ($MN)
Table 39 Europe Schizophrenia Drugs Market Outlook, By Application (2016-2026) ($MN)
Table 40 Europe Schizophrenia Drugs Market Outlook, By End User (2016-2026) ($MN)
Table 41 Asia Pacific Schizophrenia Drugs Market Outlook, By Country (2016-2026) ($MN)
Table 42 Asia Pacific Schizophrenia Drugs Market Outlook, By Type (2016-2026) ($MN)
Table 43 Asia Pacific Schizophrenia Drugs Market Outlook, By Therapeutic Class (2016-2026) ($MN)
Table 44 Asia Pacific Schizophrenia Drugs Market Outlook, By Treatment Type (2016-2026) ($MN)
Table 45 Asia Pacific Schizophrenia Drugs Market Outlook, By Application (2016-2026) ($MN)
Table 46 Asia Pacific Schizophrenia Drugs Market Outlook, By End User (2016-2026) ($MN)
Table 47 South America Schizophrenia Drugs Market Outlook, By Country (2016-2026) ($MN)
Table 48 South America Schizophrenia Drugs Market Outlook, By Type (2016-2026) ($MN)
Table 49 South America Schizophrenia Drugs Market Outlook, By Therapeutic Class (2016-2026) ($MN)
Table 50 South America Schizophrenia Drugs Market Outlook, By Treatment Type (2016-2026) ($MN)
Table 51 South America Schizophrenia Drugs Market Outlook, By Application (2016-2026) ($MN)
Table 52 South America Schizophrenia Drugs Market Outlook, By End User (2016-2026) ($MN)
Table 53 Middle East & Africa Schizophrenia Drugs Market Outlook, By Country (2016-2026) ($MN)
Table 54 Middle East & Africa Schizophrenia Drugs Market Outlook, By Type (2016-2026) ($MN)
Table 55 Middle East & Africa Schizophrenia Drugs Market Outlook, By Therapeutic Class (2016-2026) ($MN)
Table 56 Middle East & Africa Schizophrenia Drugs Market Outlook, By Treatment Type (2016-2026) ($MN)
Table 57 Middle East & Africa Schizophrenia Drugs Market Outlook, By Application (2016-2026) ($MN)
Table 58 Middle East & Africa Schizophrenia Drugs Market Outlook, By End User (2016-2026) ($MN)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Eli Lilly
  • Johnson & Johnson
  • Pfizer
  • Bristol-Myers Squibb
  • Vanda Pharma
  • Otsuka Pharma
  • Alkermes
  • Sumitomo Dainippon
  • Allergan
  • AstraZeneca
  • Titan Pharmaceutical
  • Alexza Pharmaceuticals
  • Novartis
  • Yoshitomi Yakuhin Corporation
  • Braeburn Pharmaceuticals
  • Merck & Co
Note: Product cover images may vary from those shown
Adroll
adroll